ArticleBrain : a journal of neurology2025
Plasma pTau181 and amyloid markers predict conversion to dementia in idiopathic REM sleep behaviour disorder.
Article in Brain : a journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Neuropsychological Tests for Detecting Prodromal DLB: A Systematic Review.European journal of neurology · 2026Pooled it
- Brain-first and body-first subtypes of Lewy body disease.Nature reviews. Neurology · 2026Review
- Co- and Multi-Pathologies in Parkinson's Disease: An International Parkinson and Movement Disorder Society Scientific Issues Committee Review.Movement disorders : official journal of the Movement Disorder Society · 2026Review
- Selective molecular and network architecture features underlie brain cortical atrophy in dementia with Lewy bodies.Journal of biomedical science · 2026Article
- Discordance Between Striatal Dopaminergic Imaging and Motor Performances in REM Sleep Behavior Disorder.Neurology open access · 2026Article
- Serum p-tau217 Is a Prognostic Indicator of Cognitive Impairment in Idiopathic REM Sleep Behavior Disorder.Annals of neurology · 2026Article
- Amyloid and Tau Co-pathology in Parkinson Disease and Atypical Parkinsonism.Current neurology and neuroscience reports · 2026Review
- Pedunculopontine-thalamic cholinergic projections in rapid eye movement sleep behaviour disorder.NPJ Parkinson's disease · 2026Article
- Where do PDD and DLB SYNdromes fit in neuronal alpha-SYNuclein biological frameworks?Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Article
- Plasma Markers of Astrocytic and Axonal Integrity in Idiopathic/Isolated REM Sleep Behavior Disorder (iRBD) as Predictors of Dementia with Lewy Bodies.Movement disorders : official journal of the Movement Disorder Society · 2025Article
- Plasma p-tau217 and Aβ42/40 as markers of Aβ pathology in the Lewy body continuum.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Comorbid Pathologies and Their Impact on Dementia with Lewy Bodies-Current View.International journal of molecular sciences · 2025Review
- Bio inspired optimization techniques for disease detection in deep learning systems.Scientific reports · 2025Article
- Markers help to predict dementia with Lewy bodies.Nature reviews. Neurology · 2025Article
Corrections and comments
- Commented on by
Authors and funding
11 authors.
Funding
Abstract
Blood-based biomarkers for Alzheimer's disease (AD) pathology have been investigated intensively as markers for AD-related neurodegeneration. Comorbid AD pathology is common in dementia with Lewy bodies (DLB). Accordingly, we hypothesized that plasma biomarkers associated with AD pathology might be useful to predict DLB in a cohort of idiopathic/isolated REM sleep behaviour disorder (iRBD), an incipient synucleinopathy. The aim of this study was to determine whether plasma amyloid-β and pTau181 biomarkers can predict DLB. This longitudinal single-centre (Canada) cohort study included 158 individuals with polysomnography-confirmed iRBD between September 2004 and October 2022, each providing blood plasma samples, who were then offered prospective follow-up. Plasma Aβ40, Aβ42 and pTau181 levels were measured using NeuroToolKit, a prototype assay panel of neurodegeneration (Roche Diagnostics International Ltd). The primary outcome was the association between plasma biomarkers at baseline and eventual development of DLB. Correlations between plasma markers and baseline cognitive tests were assessed. A total of 142 iRBD participants [109 male (77%); mean ± SD, 67.6 ± 8.0 years of age] were included in the final analysis. On prospective follow-up (2.9 ± 2.1 years after sampling), 32 individuals phenoconverted to a defined neurodegenerative syndrome (18 DLB, 13 Parkinson's disease and one multiple system atrophy). The combined phenoconvertor group had lower baseline plasma Aβ42/40 ratio compared with non-phenoconvertors (mean ± SD, 0.103 ± 0.010 versus 0.114 ± 0.012, P < 0.001) and higher pTau181 levels (0.993 ± 0.354 versus 0.784 ± 0.266 pg/ml, P = 0.008). When divided by phenoconversion subtype, significant differences were seen selectively in DLB convertors [Aβ42/40 = 0.101 ± 0.010, difference -0.011, 95% confidence interval (-0.016; -0.005), P < 0.001; pTau181 = 1.144 ± 0.326 pg/ml, difference 0.282 pg/ml, 95% confidence interval (0.146; 0.418), P < 0.001]. Cross-sectional analysis showed that plasma pTau181 (but not Aβ42/40) was correlated with cognitive tests across various domains. Our results indicate that plasma Aβ42/40 ratio and pTau181 can predict conversion to DLB in iRBD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.